AlphaStocks
6.6
Consider Buy

Repligen Corp (RGEN)

As of Sep 20, 2026, Repligen Corp (RGEN) scores 6.6/10 on AlphaStocks' five-model composite, #26 of 168 Health Care stocks.

Health Care / Biotechnology

S&P MidCap 400

$176.99

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#26out of 168 in Health Care

Is REPLIGEN CORP a Good Investment in 2026?

REPLIGEN CORP (RGEN) scores 6.6 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates REPLIGEN CORP as Strong (7/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 0.7% · ROC 5%. REPLIGEN CORP ranks #26 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE2.3Market Cap10B

Valuation

Trades at 205x earnings — significantly above sector median of 30x. Premium reflects market growth expectations.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

High PEG — growth premium · Slow Grower

Greenblatt

Caution

Earnings yield 0.7% · ROC 5%

Frequently Asked Questions

Is REPLIGEN CORP (RGEN) a good investment?
As of Sep 20, 2026, Repligen Corp (RGEN) scores 6.6/10 on AlphaStocks' five-model composite, #26 of 168 Health Care stocks. That is a middle-of-the-pack score with no strong signal either way. Trades at 205x earnings — significantly above sector median of 30x. Premium reflects market growth expectations.
What is REPLIGEN CORP's Piotroski F-Score?
REPLIGEN CORP's Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is RGEN overvalued or undervalued?
A precise fair value estimate is not available for RGEN. Trades at 205x earnings — significantly above sector median of 30x. Premium reflects market growth expectations.
How does RGEN compare to other Health Care stocks?
REPLIGEN CORP ranks #26 out of 168 stocks in the Health Care sector, placing it in the top 15% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about RGEN?
AlphaStocks evaluates RGEN using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 6.6/10.

Similar Stocks

ABBVINCYHRMY

Compare RGEN with

ABBV vs RGENINCY vs RGENHRMY vs RGEN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer